Literature DB >> 1727602

Identification of immunodominant epitopes in envelope glycoprotein of human T lymphotropic virus type II.

R B Lal1, D L Rudolph, J E Kaplan, B Hjelle, P H Levine, J E Coligan, R P Viscidi.   

Abstract

A series of synthetic peptides derived from the envelope glycoprotein of human T lymphotropic virus type II (HTLV-II) was used in an enzyme immunoassay to determine the immunodominant epitopes of envelope glycoprotein. Of the 11 synthetic peptides spanning the external glycoprotein of HTLV-II (gp52) and the 3 from the transmembrane protein (gp21), 3 peptides from gp52 (termed Env-20(85-102), Env-202(173-209), and Env-203(219-256] reacted with most of the polymerase chain reaction-confirmed HTLV-II specimens (83, 95, and 76%, respectively); all other peptides reacted minimally with these specimens. Env-202(173-209) reacted with a greater percentage (91 to 100%) of specimens from different risk groups, including intravenous drug users (n = 30), North American Indians (n = 13), Guaymi Indians from Panama (n = 22), and routine U.S. blood donors (n = 34), when compared with Env-20(85-102) (73 to 100%) or Env-203(219-256) (68 to 83%). Furthermore, Env-20(85-102) and Env-202(173-209) had some reactivity (8-25%) with sera from HTLV-I-infected individuals, whereas Env-203(219-256) reacted with 58% of HTLV-I specimens. We conclude that peptides Env-20(85-102) and Env-202(173-209) represent the type-specific immunodominant epitopes of HTLV-II external glycoprotein.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1727602     DOI: 10.1016/0042-6822(92)90081-y

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  6 in total

1.  Complete nucleotide sequence of an Amerindian human T-cell lymphotropic virus type II (HTLV-II) isolate: identification of a variant HTLV-II subtype b from a Guaymi Indian.

Authors:  D Pardi; W M Switzer; K G Hadlock; J E Kaplan; R B Lal; T M Folks
Journal:  J Virol       Date:  1993-08       Impact factor: 5.103

2.  Novel Genetic Constructs for Production of Recombinant HTLV-1/2 Antigens and Evaluation of Their Reactivity to Plasma Samples from HTLV-1-Infected Patients.

Authors:  Ueriton Dias de Oliveira; Fred Luciano Neves Santos; Bernardo Galvão-Castro; Marco Aurelio Krieger; Nilson Ivo Tonin Zanchin
Journal:  J Clin Microbiol       Date:  2021-03-19       Impact factor: 5.948

3.  Multi-Epitope Protein as a Tool of Serological Diagnostic Development for HTLV-1 and HTLV-2 Infections.

Authors:  Gabriela de Melo Franco; Anderson Santos da Rocha; Laura Jorge Cox; Danielle Soares de Oliveira Daian E Silva; Débora Marques da Silveira E Santos; Marina Lobato Martins; Luis Claudio Romanelli; Ricardo Ishak; Antonio C R Vallinoto; Maria Rosa Q Bomfim; Adele Caterino-de-Araujo; Jordana G A Coelho-Dos-Reis; Flávio Guimarães da Fonseca; Edel Figueiredo Barbosa-Stancioli
Journal:  Front Public Health       Date:  2022-05-23

4.  Identification and characterization of an extended Tax protein in human T-cell lymphotropic virus type II subtype b isolates.

Authors:  D Pardi; J E Kaplan; J E Coligan; T M Folks; R B Lal
Journal:  J Virol       Date:  1993-12       Impact factor: 5.103

5.  Analysis of functional conservation in the surface and transmembrane glycoprotein subunits of human T-cell leukemia virus type 1 (HTLV-1) and HTLV-2.

Authors:  A R Rosenberg; L Delamarre; A Preira; M C Dokhélar
Journal:  J Virol       Date:  1998-09       Impact factor: 5.103

6.  Mapping of homologous, amino-terminal neutralizing regions of human T-cell lymphotropic virus type I and II gp46 envelope glycoproteins.

Authors:  T J Palker; E R Riggs; D E Spragion; A J Muir; R M Scearce; R R Randall; M W McAdams; A McKnight; P R Clapham; R A Weiss
Journal:  J Virol       Date:  1992-10       Impact factor: 5.103

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.